Cancer Stocks That Are Advancing the Future of Oncology Care
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Verastem Oncology to Present at Upcoming Investor Conferences
Verastem Q1 Earnings Call Highlights
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Verastem, Inc. (NASDAQ:VSTM) Receives Average Rating of “Moderate Buy” from Analysts
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers
SG Americas Securities LLC Purchases 378,958 Shares of Verastem, Inc. $VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
What Makes Verastem (VSTM) a New Buy Stock
Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AES Corp, Airbnb, Cloudflare, Devon Energy, Levi Strauss, Lumentum, PayPal, and More
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
Verastem Oncology Announces Proposed Public Offering of Common Stock
Y Intercept Hong Kong Ltd Buys Shares of 154,917 Verastem, Inc. $VSTM
Verastem Oncology to Present at Upcoming Investor Conferences
Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript
Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
Verastem (VSTM) Upgraded to Buy: Here's Why
Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of “Buy” from Analysts
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
Best Momentum Stocks to Buy for Oct. 21
Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice
Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet